<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03622918</url>
  </required_header>
  <id_info>
    <org_study_id>3-2016-0125</org_study_id>
    <nct_id>NCT03622918</nct_id>
  </id_info>
  <brief_title>Colistin-rifampin Combination and Colistin Monotherapy in Extensively Drug-resistant Acinetobacter Baumannii</brief_title>
  <official_title>Comparison of Efficacy and Safety of Colistin-rifampin Combination and Colistin Monotherapy in Extensively Drug-resistant Acinetobacter Baumannii: Utility of the Synergy Test Results (E-test) in Vitro</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gangnam Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gangnam Severance Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aimed to confirm the utility of the synergy test results (E-tesT) in vitro
      to predict the efficacy and safety of colistin-rifampin combination and colistin monotherapy
      in extensively drug-resistant acinetobacter baumannii.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will searched pneumonia patients with CoRAB in Gangnam Severance Hospital. Subjects will
      be enrolled and randomized in a blinded fashion using a computerized random number generator
      (permuted-block randomization) for treatment with colistin and rifampin combination and
      colistin only at a ratio of 1:1. We will perform the E-test MIC:MIC ratio method to predict
      in vitro synergy of colistin and rifampin combination therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 27, 2016</start_date>
  <completion_date type="Actual">June 21, 2018</completion_date>
  <primary_completion_date type="Actual">September 24, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>microbiologic response</measure>
    <time_frame>14 days</time_frame>
    <description>negative conversion of culture study (eradication)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical response</measure>
    <time_frame>14 days</time_frame>
    <description>clinical resolution of fever, symptoms and infectious sign</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>30 days</time_frame>
    <description>mortality</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Colistin</condition>
  <condition>Rifampin</condition>
  <condition>Acinetobacter Infections</condition>
  <arm_group>
    <arm_group_label>colistin monotherapy</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>The subjects will be treated with colistin monotherapy. Colistin (100 mg, colistin sodium methanesulfonate, SCD Pharm., Seoul, Korea) will be intravenously administered with 100 mL of normal saline with 8 hours interval. Treatment should be maintained daily administration for at least 7 days and up to 28 days. Duration of antibiotics treatment will be determined through discussion by pulmonology and infection specialist.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>colistin-rifampin combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subjects will be treated with colistin and rifampin combination therapy. Colistin (100 mg, colistin sodium methanesulfonate, SCD Pharm., Seoul, Korea) will be intravenously administered with 100 mL of normal saline with 8 hours interval. Rifampin (600 mg, rifampin, Yuhan, Seoul, Korea) will be orally administered daily. Treatment should be maintained daily administration for at least 7 days and up to 28 days. Duration of antibiotics treatment will be determined through discussion by pulmonology and infection specialist.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>colistin and rifampin combination therapy</intervention_name>
    <description>Colistin (100 mg, colistin sodium methanesulfonate, SCD Pharm., Seoul, Korea) will be intravenously administered with 100 mL of normal saline with 8 hours interval. Rifampin (600 mg, rifampin, Yuhan, Seoul, Korea) will be orally administered daily. Treatment should be maintained daily administration for at least 7 days and up to 28 days. Duration of antibiotics treatment will be determined through discussion by pulmonology and infection specialist.</description>
    <arm_group_label>colistin-rifampin combination</arm_group_label>
    <other_name>colistin/rifampin combination therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>colistin monotherapy</intervention_name>
    <description>. Colistin (100 mg, colistin sodium methanesulfonate, SCD Pharm., Seoul, Korea) will be intravenously administered with 100 mL of normal saline with 8 hours interval. Treatment should be maintained daily administration for at least 7 days and up to 28 days. Duration of antibiotics treatment wil be determined through discussion by pulmonology and infection specialist .</description>
    <arm_group_label>colistin monotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pneumonia, blood septicemia, urinary tract infection, or other infection or even
             colonization with evidence of extensively drug-resistant Acinetobacter baumannii
             infection

        Exclusion Criteria:

          -  Hypersensitivity reaction to colistin or rifampin

          -  use of colistin or rifampin in 15 days prior to screening

          -  evidence of extensively drug-resistant Acinetobacter baumannii infection in 15 days
             prior to screening

          -  CLcr &lt; 15 mL/min, ALT or AST &gt; 3xULN, total bilirubin &gt; 2xULN, Hb &lt; 7 gm/dL, ANC &lt;
             500/mm3, Platelet &lt; 50,000/mm3
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>July 30, 2018</study_first_submitted>
  <study_first_submitted_qc>August 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2018</study_first_posted>
  <last_update_submitted>August 6, 2018</last_update_submitted>
  <last_update_submitted_qc>August 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gangnam Severance Hospital</investigator_affiliation>
    <investigator_full_name>Min Kwang Byun</investigator_full_name>
    <investigator_title>Assisstant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acinetobacter Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Colistin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>in discuss</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

